A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Ethinyl Estradiol/Norgestimate (Ortho Cyclen®), a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

Trial Profile

A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Ethinyl Estradiol/Norgestimate (Ortho Cyclen®), a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Lomitapide (Primary) ; Ethinylestradiol/norgestimate
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Pharmacokinetics
  • Sponsors Aegerion Pharmaceuticals
  • Most Recent Events

    • 23 Mar 2015 Planned End Date changed from 1 Jun 2014 to 1 Oct 2014, according to to ClinicalTrials.gov record.
    • 23 Mar 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 01 May 2014 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top